Tag Elad Jacoby MD

CAR 2.0: The Next Generation of Synthetic Receptor–Based Cellular Therapy for Cancer

Introduction The growing clinical experience with chimeric antigen receptor (CAR) T-cells targeting CD19 has indicated that this therapy can induce remission in a high percentage of relapsed and refractory patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) or B-cell non-Hodgkin's…